This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Focused on rare disease therapeutics, this biotech firm reported a notable insider sale amid a year of substantial stock gains.
Overview
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction value of approximately $732,000, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($30.38); post-transaction value based on June 25, 2026 market close ($30.40).
1-year price change calculated using June 25, 2026 as the reference date.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.